Nanobiotix Completes Public Offering, Raising Over $100 Million
Nanobiotix announced on May 21, 2026, the final terms of its public offering, raising €85 million. The company later confirmed the total proceeds reached $100 million after exercising an overallotment option.
Nanobiotix, a late-stage clinical biotechnology company, announced on May 21, 2026, the final terms of its global public offering which was priced at €85 million. The following day, on May 22, 2026, the company confirmed that the total gross proceeds from the offering, including the full exercise of the overallotment option, amounted to approximately $100 million.
The capital raised is earmarked to accelerate Nanobiotix's core development programs. This includes advancing its lead product candidate, NBTXR3, a novel physics-based radioenhancer designed to be injected directly into solid tumors. The aim is to enhance the efficacy of radiation therapy as a primary treatment for various solid tumor types.
In addition to the financing, Nanobiotix was also selected on June 2, 2026, to join the Euronext Tech Leaders index. This index comprises the fastest-growing European technology companies, highlighting Nanobiotix's trajectory and its role in the healthcare sector.
The company's technology leverages nanoparticles that, when administered directly into a tumor before radiotherapy, increase the radiation dose delivered to the tumor. This physics-based approach is intended to improve tumor destruction without substantially increasing damage to surrounding healthy tissues, potentially broadening the applicability and improving outcomes for radiation therapy.